Dr. Antonarakis on available prostate cancer treatments driven by genetic testing

The study assessed US veterans receiving care at the Veterans Health Administration for all cancer types, including prostate cancer.

Patients classified as GC high risk had a 5-year disease progression of 40%, compared with 20% among GC low-risk patients.

The investigators identified several genetic factors, including ARID1A mutation, that correlated with survival outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint blockade.

"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.

Michael S. Leapman, MD, MHS, highlights a study of patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.

Researchers identified 9 novel susceptibility loci for prostate cancer, 7 of which were substantially more prevalent in patients of African ancestry.